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httpcense.Abstract Asthma is an inﬂammatory disease with extracellular matrix remodeling and collagen
deposition. Vascular alterations have been suggested to contribute to airway hyper responsiveness.
Vascular endothelial growth factors and metalloproteinases are mediators of airway inﬂammation
and remodeling in asthma. There are few data regarding the potential effects of anti-asthma treat-
ment on indices of air way remodeling.
Objective: This study investigates the role of VEGF, MMP-9 in the pathogenesis of asthma and
their role as index of remodeling, markers of inﬂammation in symptomatic bronchial asthma on low
dose ICS. Also we evaluate the role of adding long acting B2 agonist for 6 weeks in airway remod-
eling for the symptomatic asthmatic patients on low dose ICS.
Methods: VEGF and MMP-9 were measured in sputum of healthy control, and bronchial
asthma patients before and after the addition of long acting B2 agonists. Also we evaluated whether
VEGF correlated with MMP-9 in symptomatic bronchial asthma receiving low or moderate dose of
ICS.
Results: Levels of VEGF and MMP-9 are signiﬁcantly higher in sputum of bronchial asthma
than in healthy controls. The mean level of VEGF, MMP-9 in sputum of bronchial asthma patients
on low to moderate dose of ICS was 2500 pg/ml ± 750, 33.3 ng/ml ± 16.7. After 6 weeks of treat-
ment with long acting B2 agonists there was a reduction in the mean levels of both VEGF, MMP-9
1750 pg/ml ± 250, 27.4 ng/ml ± l3. Also there was a signiﬁcant correlation between the levels of
VEGF and MMP-9 in healthy subjects and patients with bronchial asthma. There was a signiﬁcant
correlation between both VEGF MMP-9 and the sputum eosinophils and neutrophil in patients
with bronchial asthma before adding long acting B2 agonists.
Conclusion: Symptomatic patients with bronchial asthma on a low dose ICS have elevated levels
of VEGF, MMP-9. There was an interrelationship between VEGF and MMP-9, this ﬁnding sug-
gests that VEGF signaling regulates MMP-9 expression, and plays a critical role in the maintenance
of asthma. VEGF, MMP-9 could be considered as important markers of airway remodeling incom (J. Osman).
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Table 1 Data of all patients includ
Mean age
Sex, M/F
%Predicted FEVI for patients on low
dose TCS
%Predicted FEVI 6 weeks after additio
of LABA to ICS
PD20 on low to moderate dose ICS
PD20 after 6 weeks of LABA an ICS
Table 2 Sputum levels of VEGF a
Subject
Markers BA patien
VEGF 2500 pg/m
MMP-9 33.3 ng/m
546 S. Jehan et al.asthma. The addition of regular long acting B2 agonist to low or moderate dose ICS in symptomatic
bronchial asthma patients had a beneﬁcial effect on the air way remodeling markers in a way that
they may potentate the anti-inﬂammatory effects of ICS on inﬂammatory cells.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction and aim of the work
In patients with asthma who remain symptomatic in spite of
low to moderate doses of inhaled corticosteroid the asthma
guide lines suggest either an increased dose of ICS or addi-
tion of long acting B2 agonist. There are very few studies on
the implication role of these medications on the remodeling
process that occurs in the air way wall [1,3,4]. Airway
remodeling is due to excess extracellular matrix deposition
in the airway walls which leads to subepithelial collagen
deposition [2,5]. Airway remodeling leads to irreversible air-
way obstruction that makes bronchial asthma uncontrolla-
ble. Airway remodeling, is structural changes in airway
wall components it’s thought to result from airway inﬂam-
mation, worsening inﬂammation lead to more long term
remodeling, and the potential for worse ﬁxed airway nar-
rowing and bronchial hyper reactivity [7]. Asthma and
chronic bronchitis are inﬂammatory diseases with extracellu-
lar matrix remodeling and collagen deposition, increased
angiogenesis, connective tissue deposition and cellular prolif-
eration of myoﬁbroblast [7,8].
Vascular alterations have been suggested to contribute to
airway hyper-responsiveness. VEGF is an endothelial cell spe-
ciﬁc mitogenic peptide and plays a key role in vasculogenesis,
also it increases vascular permeability, so that plasma pro-
teins, and other mediators, cells can leak into the extracellu-
lar space that allows the migration of inﬂammatory cells into
airways [2,3,6].
Vascular endothelial growth factor is a mediator of vascu-
lar and extra cellular remodeling, and inﬂammation that en-
hances antigen sensitization. Matrix metalloproteinases are a
large family of zinc and calcium dependent endopeptidases,
with distinct substrate speciﬁcities, that can degrade most com-ed in the study.
32 ± 11
10/8
to moderate 70 ± 11
n 86 ± 11
0.023 ug/ml
0.064 ug/ml
nd MMP-9 in all subjects.
ts on low dose ICS
l ± 750
l ± 167ponents of the extra cellular matrix. MMP-9 is one of the ma-
jor proteinases that is involved in airway remodeling and
inﬂammation [9,10].
In the present study we evaluate the possible involvement
of VEGF, MMP-9 in the pathogenesis of asthma, an addi-
tional aim is to quantify the relative effect of long acting
B2 agonist, on VEGF, MMP-9 as index of remodeling in
symptomatic subjects with asthma already on low to moder-
ate dose of ICS.
Subjects and methods
This study was carried out on 18 symptomatic bronchial asth-
ma patients receiving low to moderate dose ICS and ten
healthy controls. Long acting B2 agonist was prescribed for
6 weeks for all patients, spirometric pulmonary functions air-
way responsiveness to metacholine. PD20 before and after
addition of long acting B2 agonists was measured (Table 1).
Sputum induction was obtained and levels of VEGF, MMP-
9 were determined twice for all patients, by enzyme immunoas-
say according to the manufacturer’s protocol.
Results
Table 1 showed all the patients’ data including their base line
FEVI, PD20 M after 6 weeks of long acting B2 agonists
(LABA). The difference between base line PFTs 6 weeks after
LABA was found to be of statistically signiﬁcant value
P< 0.05.
The VEGF in sputa of all subjects have been shown in
Table 2. The mean VEGF in healthy control subjects was
350 pg/ml ± 100 compared to 2500 pg/ml ± 750 as a base line
for the bronchial asthma who were receiving low or moderate
dose ICS, after 6 weeks of LABA addition the mean level of
VEGF was 1750 ± 250. The mean level of MMP-9 in sputum
of healthy control was 6.5 mg/ml ± 1.4. Compared to mean le-
vel of 33.3 ng/ml ± 16.7 as base line level for the patients who
were already receiving low or moderate dose ICS, the differ-
ence between the control and the patient levels was found to
be of statistically signiﬁcant value P< 0.01, after 6 weeks of
addition of LABA the mean level of sputum MMP-9 reduced
to 27.4 ng/ml ± 13. The difference between the base line level
while the patient was on low to moderate dose ICS, and
6 weeks after adding LABA was found to be of non signiﬁcant
value for both of the VEGF and MMP-9 (Table 2).BA after receiving LABA Healthy control
1750 pg/ml ± 250 350 pg/ml ± 100
27.4 ng/ml/ ± 13 6.5 ng/ml ± 1.4
Figure 1 Correlation between the concentrations of VEGE and
MMP-9 in the sputum.
Bronchial asthma and airway remodeling markers 547Fig. 1 showed that the levels of MMP-9 correlated signiﬁ-
cantly with VEGF levels in patients before and after LABA,
and in the healthy control (r= 0.813, P< 0.05).
The levels of VEGF, MMP-9 in sputum obtained
from patients were signiﬁcantly inversely correlated with
the percent predicted FEVI before and after 6 weeks of
LABA. Airway responsiveness was assessed by measuring
PD20 for metacholine and there was a signiﬁcant positive
correlation between the PD20 M. and MMP-9, VEGF
before and after the addition of long acting B2 agonist
Table 3.
Sputum VEGF, MMP-9 correlates signiﬁcantly with
sputum eosinophils and neutrophils before LABA. However
there was non signiﬁcant correlation between the previous
sputum markers and the eosinophilic neutrophilic sputum cell
count after 6 weeks of long acting B2 agonists (Table 4).Table 3 Correlation between VEGF, MMP-9 in sputum, and the p
PFT VEGF
r
FEVI% predict with ICS 0.0716
FEVI% predict with ICS + LABA 0.0514
PD20 metacholine with ICS 0.0824
PD20 metacholine with ICS + LABA 0.0986
Table 4 Correlation between VEGF, MMP-9 and eosinophil, neut
Diﬀerential cell count of sputum eosinophil VEGF
r
Patients on low dose ICS
Sputum eosinophil 106 cell/ml 0.894
Sputum neutrophils 106 cell/ml 0.758
Patients on ICS and after 6 weeks of LABA addition
Sputum eosinophil 106 cell/ml 0.391
Sputum neutrophil 106 cell/ml 0.510Discussion
Vascular endothelial growth factor is an endothelial cell spe-
ciﬁc mitogen that has been shown to play a key role in vascu-
logenesis and angiogensis [2].
VEGF is a potent stimulator of inﬂammation, airway
remodeling, physiologic dysregulation that augments antigen
sensitization and stimulation, and inﬂammatory cell migration
[3] MMP9 plays a role in chronic inﬂammation and remodel-
ing in asthma [8,10]. The aim of this work is to study the role
of VEGF, MMP9 in the pathogenesis of bronchial asthma
who remain symptomatic in spite of a low to moderate dose
of ICS and to quantify the role of addition long acting B2 ago-
nist, on the airway inﬂammation that underlies asthma, and
airway remodeling. VEGF, MMP9 were taken as index of
air way remodeling in symptomatic patients with already low
to moderate dose of ICS.
This study showed that the levels of VEGF and MMP9 are
signiﬁcantly higher in induced sputum of bronchial asthma pa-
tients than in control subjects. The levels of VEGF, MMP9
were measured initially for the bronchial asthma patients,
who were receiving a low or a moderate dose of inhaled corti-
costeroids and the mean levels were 2500 ± 750 pg/ml,
33.7 ± 16.7 ng/ml respectively. After 6 weeks of addition long
acting B2 agonist the mean levels reduced to 1750 ± 250 pg/
ml, 27.4 ng/ml ± respectively and the difference was found
to be of non signiﬁcant value. Lee et al 2004, reported that
there has been controversy regarding the potential adverse ef-
fects of regular B2 agonist therapy. Concerns included the pos-
sibility of worsening of air way inﬂammation, and increased
long term damage through excessive airway remodeling, there-
by enhancing airway hyper responsiveness. Our results indicate
that adding long acting B2 agonist for 6 weeks was associated
with direct effect on angiogenic growth factors, we could say
that B2 agonists may have potential anti-inﬂammatory proper-
ties that are complementary to the effects of ICS. Spiekermanulmonary function in relation to treatment.
MMP-9
p r p
<0.05 0.0590 <0.05
<0.05 0.0680 <0.05
<0.05 0.0564 <0.05
<0.05 0.042 <0.05
rophil count before and after addition of B2 agonists.
MMP-9
p r p
<0.05 0.865 <0.05
<0.05 0.698 <0.05
>0.05 Ns 0.411 P0.06 Ns
>0.05 Ns 0.389 =0.009 Ns
548 S. Jehan et al.et al. (2002), in their recent in vitro studies reported that B2
agonists caused a propranolol sensitive CAMP- dependent
activation and nuclear translocation of glucocorticoid recep-
tors in human lung ﬁbroblast and vascular smooth muscle
cells, this provides a potential mechanism for complementary
anti inﬂammatory, cellular effects of ICS and B2 agonists [8].
We realized that longer duration of long acting B2 agonist
and ICS would cause a signiﬁcant reduction of both VEGF,
MMP9 in the airway walls. Other studies carried by Asai
et al. 2002 concluded that ICS, and B2 agonists did not pro-
hibit totally airway vascularity, also they reported that using
VEGFR inhibitors, might be an effective future treatment
for symptomatic bronchial asthma patients. This study demon-
strated that there was a positive correlation between both
VEGF, MMP9 and the eosinophil, neutrophil sputum cell
count. However there was no signiﬁcant correlation between
the sputum markers and the differential, sputum cell count
after 6 weeks of long acting B2 agonists. This could be ex-
plained by the fact that there are other active sources that par-
ticipate in VEGF, MMP9 production rather than neutrophil
and eosinophil or the absence of the major physiologic inhib-
itors of both VEGF, MMP9 named TIMPs in symptomatic
bronchial asthma patients. This study demonstrates that there
was a signiﬁcant correlation between VEGF and MMP9 levels,
consistent with those observation is the study conducted by
Lee et al. (2004) using a murine model of asthma induced by
toluidene diisocyanate. They found that the asthma model
exhibits typical pathophysiologic features of asthma in lungs,
and increase in the levels of VEGF and MMP9. Moreover,
administration of VEGF receptor inhibitors reduces the path-
ophysiologic signs of asthma and the increased expression of
MMP9, taken together these observations have suggested that
VEGF signaling regulates MMP9 expression and plays an
important role in initiation and up holing of asthmatic signs.
In conclusion we found that after the 6 week treatment of
bronchial asthma patients with long acting B2 agonists already
on ICS there was no worsening of parameters of airway vascu-
lar remodeling, and there could be a modifying effect by low
dose of ICS on airway vascularity and a likely additive effectfollowing B2 agonist complementary to effect of ICS, further
studies are required to conﬁrm these data and to assess mech-
anisms of such effects. Based on the marked increase of VEGF
and MMP9 in sputum of symptomatic bronchial asthma pa-
tients on low or moderate dose ICS, we could conclude that
VEGF plays a crucial role in the pathogenesis of tissue remod-
eling and air way obstruction. Also a close relationship was
found between VEGF and MMP9 expression, this would raise
the suggestion of using VEGF receptors inhibitors in the fu-
ture to reverse all pathophysiologic signs and reduce the in-
creased expression of MMP9 in bronchial asthma and other
airway inﬂammatory diseases.
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